GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Unearned Premiums

ARCA biopharma (FRA:HQ10) Unearned Premiums


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Unearned Premiums?

Unearned Premiums only applies to insurance companies.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.